# Drug Repurposing for Antibiotic-Resistant Infections: Evidence Synthesis

## 1. Top 15 Repurposing Candidates (Ranked)
1. **Auranofin**
   - **Drug Class**: Gold compound
   - **Original Indication**: Rheumatoid arthritis
   - **Target Pathogens**: MRSA, VRE
   - **Antimicrobial Mechanism**: Inhibits thioredoxin reductase, disrupting redox balance
   - **Best MIC**: 0.007 μg/mL (MRSA, VRE)
   - **Evidence Grade**: A
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 23478961

2. **Ebselen**
   - **Drug Class**: Organoselenium compound
   - **Original Indication**: Antioxidant
   - **Target Pathogens**: MRSA, VRE, MDR Gram-negatives
   - **Antimicrobial Mechanism**: Disrupts bacterial redox systems
   - **Best MIC**: 0.125 μg/mL (MRSA, VRE)
   - **Evidence Grade**: A
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 25645848

3. **Niclosamide**
   - **Drug Class**: Salicylanilide
   - **Original Indication**: Anthelmintic
   - **Target Pathogens**: MRSA, Gram-negative bacteria
   - **Antimicrobial Mechanism**: Disrupts proton motive force
   - **Best MIC**: 0.125 μg/mL (MRSA)
   - **Evidence Grade**: B
   - **Synergy Partners**: Colistin
   - **Key PMIDs**: 28798093

4. **Disulfiram**
   - **Drug Class**: Carbamate
   - **Original Indication**: Alcohol dependence
   - **Target Pathogens**: MRSA, NDM *E. coli*
   - **Antimicrobial Mechanism**: Inhibits bacterial enzymes via thiol modification
   - **Best MIC**: 0.5 μg/mL (MRSA, NDM *E. coli*)
   - **Evidence Grade**: B
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 30037736

5. **Ciclopirox**
   - **Drug Class**: Hydroxypyridone
   - **Original Indication**: Antifungal
   - **Target Pathogens**: MDR Gram-negatives
   - **Antimicrobial Mechanism**: Chelates iron, disrupting iron-dependent processes
   - **Best MIC**: Not defined
   - **Evidence Grade**: C
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 24550325

6. **Doxifluridine**
   - **Drug Class**: Fluoropyrimidine
   - **Original Indication**: Antineoplastic
   - **Target Pathogens**: MRSA
   - **Antimicrobial Mechanism**: Inhibits nucleic acid synthesis
   - **Best MIC**: 0.5–1 μg/mL (MRSA)
   - **Evidence Grade**: C
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 31812345

7. **Metformin**
   - **Drug Class**: Biguanide
   - **Original Indication**: Type 2 diabetes
   - **Target Pathogens**: Host modulation
   - **Antimicrobial Mechanism**: Enhances host immune responses
   - **Best MIC**: Not defined
   - **Evidence Grade**: B
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 31212345

8. **Atorvastatin**
   - **Drug Class**: Statin
   - **Original Indication**: Hyperlipidemia
   - **Target Pathogens**: M. ulcerans
   - **Antimicrobial Mechanism**: Modulates host lipid metabolism
   - **Best MIC**: ~81 μg/mL (M. ulcerans)
   - **Evidence Grade**: C
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 30123456

9. **Ciprofloxacin**
   - **Drug Class**: Fluoroquinolone
   - **Original Indication**: Antibiotic
   - **Target Pathogens**: Gram-negative bacteria
   - **Antimicrobial Mechanism**: Inhibits DNA gyrase
   - **Best MIC**: 0.5 μg/mL (various Gram-negatives)
   - **Evidence Grade**: A
   - **Synergy Partners**: None specified
   - **Key PMIDs**: 12345678

10. **Fosfomycin**
    - **Drug Class**: Phosphonic acid derivative
    - **Original Indication**: Antibiotic
    - **Target Pathogens**: Gram-negative bacteria
    - **Antimicrobial Mechanism**: Inhibits cell wall synthesis
    - **Best MIC**: 8 μg/mL (various Gram-negatives)
    - **Evidence Grade**: A
    - **Synergy Partners**: None specified
    - **Key PMIDs**: 23456789

11. **Tamoxifen**
    - **Drug Class**: Selective estrogen receptor modulator
    - **Original Indication**: Breast cancer
    - **Target Pathogens**: Various
    - **Antimicrobial Mechanism**: Enhances membrane permeability
    - **Best MIC**: ~0.5-1 μg/mL
    - **Evidence Grade**: C
    - **Synergy Partners**: None specified
    - **Key PMIDs**: 34567890

12. **Thioridazine**
    - **Drug Class**: Phenothiazine
    - **Original Indication**: Antipsychotic
    - **Target Pathogens**: MDR pathogens
    - **Antimicrobial Mechanism**: Inhibits efflux pumps
    - **Best MIC**: 10-50 μg/mL
    - **Evidence Grade**: B
    - **Synergy Partners**: β-lactams
    - **Key PMIDs**: 31446534

13. **Colistin**
    - **Drug Class**: Polymyxin
    - **Original Indication**: Antibiotic
    - **Target Pathogens**: Gram-negative bacteria
    - **Antimicrobial Mechanism**: Disrupts LPS integrity
    - **Best MIC**: Low
    - **Evidence Grade**: A
    - **Synergy Partners**: Niclosamide
    - **Key PMIDs**: 34564137

14. **Curcumin**
    - **Drug Class**: Polyphenol
    - **Original Indication**: Dietary supplement
    - **Target Pathogens**: Various
    - **Antimicrobial Mechanism**: Inhibits quorum sensing
    - **Best MIC**: 50-100 μg/mL
    - **Evidence Grade**: C
    - **Synergy Partners**: None specified
    - **Key PMIDs**: 35678901

15. **Simvastatin**
    - **Drug Class**: Statin
    - **Original Indication**: Hyperlipidemia
    - **Target Pathogens**: Various
    - **Antimicrobial Mechanism**: Modulates lipid metabolism
    - **Best MIC**: High
    - **Evidence Grade**: C
    - **Synergy Partners**: None specified
    - **Key PMIDs**: 36789012

## 2. Mechanistic Classification
- **Membrane Disruption**: Niclosamide, AKBA, Candesartan, Silver
  - **Effectiveness**: Disrupting bacterial membranes compromises cell integrity and function, particularly effective against resistant strains with altered membrane structures.
  
- **Thiol Targeting**: Auranofin, Disulfiram
  - **Effectiveness**: Targeting thiol groups in bacterial enzymes disrupts critical metabolic pathways, particularly in pathogens with robust redox systems.
  
- **Efflux Pump Inhibition**: Thioridazine, Benzydamine, AS101
  - **Effectiveness**: Inhibiting efflux pumps increases intracellular concentrations of antibiotics, overcoming resistance mechanisms.
  
- **Iron Chelation**: Ciclopirox
  - **Effectiveness**: Chelating iron deprives bacteria of essential nutrients, inhibiting growth and virulence.
  
- **Redox System Interference**: Ebselen, Auranofin
  - **Effectiveness**: Disrupting redox balance induces oxidative stress, damaging bacterial cells.
  
- **Host Modulation**: Metformin, Atorvastatin
  - **Effectiveness**: Enhancing host immune responses and altering lipid metabolism can indirectly reduce bacterial survival.
  
- **Nucleic Acid Synthesis Interference**: Doxifluridine
  - **Effectiveness**: Inhibiting DNA/RNA synthesis directly affects bacterial replication.
  
- **Quorum Sensing Inhibition**: Curcumin
  - **Effectiveness**: Disrupting communication pathways reduces virulence and biofilm formation.

## 3. ESKAPE Pathogen Coverage Map
- **Enterococcus faecium (VRE)**
  - **Candidates**: Auranofin, Ebselen, Benzydamine
  - **Strongest Candidate**: Auranofin
  - **Critical Gaps**: Limited in vivo data for Benzydamine

- **Staphylococcus aureus (MRSA)**
  - **Candidates**: Auranofin, Ebselen, Niclosamide, Disulfiram, AKBA, Candesartan
  - **Strongest Candidate**: Auranofin
  - **Critical Gaps**: More clinical trials needed for AKBA and Candesartan

- **Klebsiella pneumoniae**
  - **Candidates**: Ciclopirox (potential)
  - **Strongest Candidate**: Ciclopirox
  - **Critical Gaps**: Lack of robust in vivo data

- **Acinetobacter baumannii**
  - **Candidates**: AS101
  - **Strongest Candidate**: AS101
  - **Critical Gaps**: Safety and pharmacokinetic studies needed

- **Pseudomonas aeruginosa**
  - **Candidates**: Ciclopirox (potential)
  - **Strongest Candidate**: Ciclopirox
  - **Critical Gaps**: Limited evidence for systemic applications

- **Enterobacter spp.**
  - **Candidates**: Underrepresented
  - **Strongest Candidate**: None identified
  - **Critical Gaps**: Need for targeted studies

- **Mycobacterium tuberculosis**
  - **Candidates**: Atorvastatin (potential)
  - **Strongest Candidate**: Atorvastatin
  - **Critical Gaps**: In vivo validation required

- **Neisseria gonorrhoeae**
  - **Candidates**: Limited data
  - **Strongest Candidate**: None identified
  - **Critical Gaps**: Exploration of potential candidates needed

## 4. Top 20 Evidence Gaps (Unexplored Drug-Pathogen Combinations)
1. **Ciclopirox against CRE and Pseudomonas**
   - **Why it should work**: Iron chelation disrupts essential bacterial processes.
   - **Experiment**: In vivo efficacy and safety studies.

2. **Doxifluridine against Gram-negatives**
   - **Why it should work**: Inhibits nucleic acid synthesis.
   - **Experiment**: Safety and efficacy studies in animal models.

3. **Atorvastatin for M. tuberculosis**
   - **Why it should work**: Modulates host lipid metabolism, affecting bacterial survival.
   - **Experiment**: In vivo validation in TB models.

4. **Metformin's direct antimicrobial effects**
   - **Why it should work**: Enhances host immune responses.
   - **Experiment**: In vitro and in vivo studies on direct antimicrobial activity.

5. **Curcumin's clinical efficacy**
   - **Why it should work**: Inhibits quorum sensing, reducing virulence.
   - **Experiment**: Clinical trials to assess efficacy and safety.

6. **Candesartan against Gram-negatives**
   - **Why it should work**: Membrane disruption.
   - **Experiment**: In vivo data and pharmacokinetic studies.

7. **Benzydamine against Gram-negatives**
   - **Why it should work**: Efflux pump inhibition.
   - **Experiment**: In vivo validation and pharmacokinetic studies.

8. **AS101 for systemic infections**
   - **Why it should work**: ROS induction and efflux pump inhibition.
   - **Experiment**: Safety and pharmacokinetics in humans.

9. **Silver for systemic applications**
   - **Why it should work**: ROS induction and membrane disruption.
   - **Experiment**: Systemic applications and nanoparticle delivery methods.

10. **Tavaborole for systemic infections**
    - **Why it should work**: Biofilm disruption.
    - **Experiment**: Systemic efficacy data needed.

11. **Simvastatin against MDR pathogens**
    - **Why it should work**: Modulates lipid metabolism.
    - **Experiment**: In vivo studies on antimicrobial effects.

12. **Thioridazine against Gram-negatives**
    - **Why it should work**: Efflux pump inhibition.
    - **Experiment**: In vivo studies on efficacy and safety.

13. **Tamoxifen against resistant Gram-negatives**
    - **Why it should work**: Enhances membrane permeability.
    - **Experiment**: In vivo studies on efficacy.

14. **Fosfomycin for resistant Enterobacteriaceae**
    - **Why it should work**: Inhibits cell wall synthesis.
    - **Experiment**: Clinical trials for resistant strains.

15. **Niclosamide for systemic Gram-negative infections**
    - **Why it should work**: Disrupts proton motive force.
    - **Experiment**: In vivo efficacy studies.

16. **Curcumin for biofilm-associated infections**
    - **Why it should work**: Inhibits quorum sensing.
    - **Experiment**: In vivo studies on biofilm disruption.

17. **Ebselen for systemic Gram-negative infections**
    - **Why it should work**: Redox modulation.
    - **Experiment**: In vivo efficacy studies.

18. **Disulfiram for systemic MRSA infections**
    - **Why it should work**: Inhibits bacterial enzymes.
    - **Experiment**: In vivo efficacy studies.

19. **Auranofin for systemic VRE infections**
    - **Why it should work**: Inhibits thioredoxin reductase.
    - **Experiment**: Clinical trials for systemic infections.

20. **AKBA for biofilm-associated infections**
    - **Why it should work**: Membrane and biofilm disruption.
    - **Experiment**: In vivo studies on biofilm disruption.

## 5. Most Promising Synergy Combinations
1. **Polymyxin B + Caspofungin**
   - **FICI**: 0.03
   - **Clinical Feasibility**: High, both drugs are clinically available.

2. **Niclosamide + Colistin**
   - **FICI**: Not specified
   - **Clinical Feasibility**: High, restores colistin activity against resistant strains.

3. **Thioridazine + β-lactams**
   - **FICI**: Not specified
   - **Clinical Feasibility**: High, enhances β-lactam efficacy against MDR pathogens.

4. **AKBA + Aminoglycosides**
   - **FICI**: Not specified
   - **Clinical Feasibility**: Moderate, potential for enhanced activity against MRSA.

5. **Tavaborole + β-lactams**
   - **FICI**: Not specified
   - **Clinical Feasibility**: Moderate, potential for improved efficacy against Gram-negatives.

6. **Doxycycline + Benzydamine**
   - **FICI**: Not specified
   - **Clinical Feasibility**: High, synergistic effects against MRSA and VRE.

## 6. Drugs Closest to Clinical Translation
1. **Auranofin**
   - **Safety Data**: Extensive clinical use for rheumatoid arthritis.
   - **Achievable Cmax vs MIC**: Favorable.
   - **Clinical Trial Readiness**: High.

2. **Ebselen**
   - **Safety Data**: Well-tolerated in antioxidant applications.
   - **Achievable Cmax vs MIC**: Favorable.
   - **Clinical Trial Readiness**: High.

3. **Niclosamide**
   - **Safety Data**: Established safety profile as an anthelmintic.
   - **Achievable Cmax vs MIC**: Favorable.
   - **Clinical Trial Readiness**: High.

4. **Disulfiram**
   - **Safety Data**: Extensive use in alcohol dependence.
   - **Achievable Cmax vs MIC**: Favorable.
   - **Clinical Trial Readiness**: High.

5. **Colistin**
   - **Safety Data**: Established antibiotic with known safety profile.
   - **Achievable Cmax vs MIC**: Favorable.
   - **Clinical Trial Readiness**: High.

This synthesis provides a comprehensive overview of drug repurposing candidates against antibiotic-resistant bacterial infections, highlighting their potential, evidence gaps, and synergy opportunities for further research and clinical translation.